[PAPER] Safety and efficacy of rapamycin on healthspan metrics after one year: PEARL Trial Results
[PAPER] Safety and efficacy of rapamycin on healthspan metrics after one year: PEARL Trial Results
Rapamycin has been shown to have longevity-enhancing effects in murine models, but clinical data on its gerotherapeutic effects in humans remains limited. We performed a 48-week double-blinded, randomized, and placebo-controlled decentralized study (Participatory Evaluation of Aging with Rapamycin f...
This is a preprint, which means that the article has not been peer-reviewed yet. This is all part of the normal process, researchers will often present their findings before their work is published.
Here the deets!
The AgelessRx-sponsored Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) trial was a 48-week randomized, double-blind, placebo-controlled trial investigating the safety and potential efficacy of different intermittent rapamycin doses for mitigating signs of aging.
More info!